Pfizer Inc. (PFE) Shares Sold by MUFG Americas Holdings Corp

MUFG Americas Holdings Corp decreased its holdings in Pfizer Inc. (NYSE:PFE) by 3.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,148,566 shares of the biopharmaceutical company’s stock after selling 42,475 shares during the period. Pfizer comprises about 1.3% of MUFG Americas Holdings Corp’s investment portfolio, making the stock its 16th biggest holding. MUFG Americas Holdings Corp’s holdings in Pfizer were worth $41,003,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Honkamp Krueger Financial Services Inc. grew its holdings in shares of Pfizer by 5.5% in the second quarter. Honkamp Krueger Financial Services Inc. now owns 105,559 shares of the biopharmaceutical company’s stock worth $3,546,000 after acquiring an additional 5,547 shares during the period. Hamlin Capital Management LLC grew its holdings in shares of Pfizer by 1.6% in the second quarter. Hamlin Capital Management LLC now owns 2,893,544 shares of the biopharmaceutical company’s stock worth $97,194,000 after acquiring an additional 46,287 shares during the period. Heritage Wealth Advisors grew its holdings in shares of Pfizer by 1.9% in the second quarter. Heritage Wealth Advisors now owns 59,192 shares of the biopharmaceutical company’s stock worth $1,989,000 after acquiring an additional 1,109 shares during the period. Lourd Capital LLC grew its holdings in shares of Pfizer by 2.3% in the second quarter. Lourd Capital LLC now owns 30,393 shares of the biopharmaceutical company’s stock worth $1,021,000 after acquiring an additional 693 shares during the period. Finally, Nwam LLC grew its holdings in shares of Pfizer by 2.3% in the second quarter. Nwam LLC now owns 55,031 shares of the biopharmaceutical company’s stock worth $1,848,000 after acquiring an additional 1,245 shares during the period. 70.06% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. 0.06% of the stock is owned by insiders.

Several analysts recently commented on the company. BMO Capital Markets set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Thursday. Berenberg Bank set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. Societe Generale set a $40.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, January 31st. UBS Group set a $42.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Leerink Swann lifted their price objective on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $39.45.

Pfizer Inc. (PFE) opened at $36.26 on Friday. The firm has a market capitalization of $216,140.00, a price-to-earnings ratio of 10.30, a P/E/G ratio of 2.02 and a beta of 0.94. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a 52-week low of $31.67 and a 52-week high of $39.43.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same period in the previous year, the business earned $0.47 earnings per share. Pfizer’s quarterly revenue was up .6% compared to the same quarter last year. equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer declared that its Board of Directors has approved a stock buyback plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.75%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. Pfizer’s payout ratio is presently 38.64%.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thelincolnianonline.com/2018/02/18/pfizer-inc-pfe-shares-sold-by-mufg-americas-holdings-corp-2.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply